EPA can be enzymatically converted to resolvin E1 (RvE1) in vivo and affect atherosclerotic inflammation and mediate the immune response through the EPA/RvE1/ChemR23 pathway, thereby improving the outcomes of atherosclerosis-related cardiovascular disease (Carracedo et al., 2019). The gene discussed is CMKLR1; the disease is atherosclerosis.